Background-Stimulation of ␤ 1 -and ␤ 2 -adrenergic receptors (ARs) in the heart results in positive inotropy. In contrast, it has been reported that the ␤ 3 AR is also expressed in the human heart and that its stimulation leads to negative inotropic effects. Methods and Results-To better understand the role of ␤ 3 ARs in cardiac function, we generated transgenic mice with cardiac-specific overexpression of 330 fmol/mg protein of the human ␤ 3 AR (TG␤ 3 mice). Hemodynamic characterization was performed by cardiac catheterization in closed-chest anesthetized mice, by pressure-volume-loop analysis, and by echocardiography in conscious mice. After propranolol blockade of endogenous ␤ 1 -and ␤ 2 ARs, isoproterenol resulted in an increase in contractility in the TG␤ 3 mice (30%), with no effect in wild-type mice. Similarly, stimulation with the selective human ␤ 3 AR agonist L-755,507 significantly increased contractility in the TG␤ 3 mice (160%), with no effect in wild-type mice, as determined by hemodynamic measurements and by end-systolic pressure-volume relations. The underlying mechanism of the positive inotropy incurred with L-755,507 in the TG␤ 3 mice was investigated in terms of ␤ 3 AR-G-protein coupling and adenylyl cyclase activation. Stimulation of cardiac membranes from TG␤ 3 mice with L-755,507 resulted in a pertussis toxin-insensitive 1.33-fold increase in [ 35 S]GTP␥S loading and a 1.6-fold increase in adenylyl cyclase activity.
␤-Adrenergic receptors (␤ARs) are members of a family of G protein-coupled receptors that are stimulated by naturally occurring catecholamines. In the heart, both the ␤ 1 -and ␤ 2 AR subtypes are known to modulate cardiac function by producing positive inotropic and chronotropic effects. A third ␤AR subtype, the ␤ 3 AR, 1,2 has been found primarily in adipose tissue of rodents, in human omental tissue, and in the brown adipose tissue of newborns. 2 In human heart 3, 4 and mouse heart, 5 ␤ 3 AR transcripts have been detected by sensitive methods, such as RNase protection assays and reverse transcription-polymerase chain reaction assays. Like ␤ 1 -and ␤ 2 ARs, the ␤ 3 AR couples to G s to activate adenylyl cyclase, which in adipose tissue leads to lipolysis or thermogenesis. 2 It has also been shown that the ␤ 3 AR can couple to G i , resulting in the attenuation of adenylyl cyclase stimulation and in the activation of the mitogen-activated protein kinase (MAPK) pathway. 6, 7 Gauthier et al 8 proposed that the ␤ 3 AR is present and functional in the human heart. They showed that stimulation of human ventricular endomyocardial biopsies with BRL 37344, a ␤ 3 AR agonist, leads to a pertussis toxin (PTX)-sensitive negative inotropic effect, suggesting that in this system the ␤ 3 AR is coupled to G i . 8 To further explore the physiological consequences of activation of the ␤ 3 AR in cardiac contractility, we generated transgenic mice with cardiac-specific overexpression of the human ␤ 3 AR (TG␤ 3 mice). ␤ 3 AR signal transduction was assessed both in vitro in cardiac membranes and in vivo by catheterization in intact mice.
Methods

Transgene Construction
The ␣MHC-HA␤ 3 AR transgene was constructed from a 5.5-kb SalI-SalI fragment containing the murine ␣MHC promoter 9 and the EcoRI-XbaI fragment containing the human ␤ 3 AR coding sequence (1 to 402 amino acids) with an NH 2 -terminal hemagglutinin (HA) tag. 10 The ␣MHC-HA␤ 3 AR transgene was digested with SpeI-SacI, purified with CsCl, and used for nuclear injection of oocytes by the Duke Comprehensive Cancer Center Transgenic Mouse Facility. One line of C57B6SJL/J mice that expressed the HA␤ 3 AR transgene was established. Studies were performed on mice 2 to 8 months of age.
Northern Blotting
mRNAs from heart tissue of both TG␤ 3 and wild-type (WT) mice were separated by electrophoresis and transferred onto a nylon filter (Schleicher & Schuell) by standard techniques. 11 The filter was hybridized to a random primer radiolabeled probe corresponding to the entire coding region of the human ␤ 3 AR clone.
Ligand Binding, GTP␥S Loading, and Adenylyl Cyclase Assays
Crude membranes were prepared from excised hearts, and ligand binding assays were performed as previously described. 9 [ 35 S]GTP␥S loading and adenylyl cyclase assays were performed as previously described. 12, 13 Transthoracic Echocardiography 2D guided M-mode echocardiography was performed in conscious mice with an HDI 5000 echocardiograph (ATL) as previously described. 14
Myocyte Isolation
Adult myocytes were isolated from WT and TG␤ 3 mice as previously described. 15 After isolation, myocytes were fixed in 3% paraformaldehyde, and length and width were measured with a video edge-detection system (Crescent Electronics).
Hemodynamic Evaluation in Intact Anesthetized Mice
Cardiac catheterization was performed as described previously. 14 Mice were anesthetized with a mixture of ketamine (100 mg/kg IP) and xylazine (2.5 mg/kg IP), and after bilateral vagotomy, a 1.4F high-fidelity micromanometer catheter (Millar Instruments) was inserted into the right carotid artery and advanced retrogradely across the aortic valve.
Experimental Protocols
Protocol 1
Hemodynamic measurements were recorded at baseline and 45 to 60 seconds after the injection of isoproterenol (1000 pg IV). After hemodynamics returned to baseline, propranolol (0.05 g/g body weight [BW] IV) was administered to block ␤ 1 -and ␤ 2 ARs. After return to baseline, hemodynamic measurements were again recorded before and after administration of isoproterenol.
Protocol 2
Hemodynamic measurements were recorded at baseline and 90 to 120 seconds after the injection of an incremental dose of L755,507 (0.25 to 4.0 g IV).
Pressure-Volume Measurements
In separate experiments, in vivo pressure-volume (P-V) relations were determined as previously described. 14 Mice were anesthetized as described above and maintained by the administration of 0.5% to 1.0% isoflurane. The space and time resolutions of the sonomicrometry system are 0.015 mm and 0.001 seconds, respectively.
Data and Statistical Analyses
The digitized data were analyzed with a computer algorithm as previously described. 14 
Results
Generation of ␤ 3 AR Overexpressing Mice
To investigate the biochemical and physiological consequences of overexpression of ␤ 3 ARs in heart, we generated transgenic mice with cardiac-restricted overexpression of the human ␤ 3 AR (TG␤ 3 ). Transgene expression was documented by Northern analysis of mRNA from the heart ( Figure 1A ). As shown, expression was detected only in TG␤ 3 mice and was absent in WT mice. Several transcripts were detected, corresponding to 1.4 kb and 3.0 to 4.0 kb in size. The range in sizes is probably the result of the utilization of a variety of transcriptional termination signals downstream of the integration site.
Characterization of the ␤ 3 AR Expression in TG␤ 3 Mice
The level of ␤ 3 AR expression in cardiac membranes of the TG␤ 3 mice was quantified by use of competition ligand- Figure 1 . Characterization of overexpression of ␤ 3 AR in TG␤ 3 and WT mice. A, Northern blot for human ␤ 3 AR expression in TG␤ 3 mice. mRNA (10 g) from TG␤ 3 and WT hearts was probed with entire coding sequence of human ␤ 3 AR clone. Equal loading of sample was confirmed by reprobing filter with human ␤-actin probe. B, Competition binding assays were performed on membranes prepared from TG␤ 3 (nϭ3) and WT (nϭ3) hearts incubated with 500 pmol/L [ 125 I]ICYP and various concentrations of pindolol. Nonspecific binding was determined with 0.1 mmol/L isoproterenol and was Ϸ30% and 70% of total binding in TG␤ 3 and WT membranes, respectively. Estimated B max was calculated with GraphPAD software equation for competitive binding to 2 receptor types with different K d for radioligand (K d s are constants). K d for binding [ 125 I]ICYP to ␤ 1 /␤ 2 ARs is 0.030 nmol/L, 24 and that for binding ␤ 3 ARs is 1 nmol/L. 2 binding assays ( Figure 1B ) with the radioligand [ 125 I]iodocyanopindolol ([ 125 I]ICYP) and increasing concentrations of unlabeled pindolol. Binding data from membranes prepared from WT and TG␤ 3 heart extracts were fit by a biphasic curve with a very small high-affinity component corresponding to ␤ 1 -and ␤ 2 ARs and a low-affinity phase corresponding to displacement of pindolol from the ␤ 3 ARs. From these data, the number of ␤ 3 ARs expressed in hearts of TG␤ 3 mice (B max ) was calculated with GraphPAD software and was determined to be 330Ϯ36 fmol/mg membrane protein.
To characterize the endogenous expression levels of ␤ 1and ␤ 2 ARs in the transgenic heart, saturation binding experiments were performed with 5 to 200 pmol/L [ 125 I]ICYP. At these relatively low concentrations and because of the low affinity of the ␤ 3 ARs for the radioligand, only ␤ 1 -and ␤ 2 ARs will be bound, with minimal contribution from the ␤ 3 ARs. Results in Figure 1C show that the B max for ␤ 1 -and ␤ 2 ARs is reduced from 53.6Ϯ4.1 fmol/mg in the WT mice to 34.5Ϯ2.0 fmol/mg in TG␤ 3 mice (PϽ0.002 between WT and TG␤ 3 mice). Competition binding experiments with the ␤ 2 ARselective antagonist ICI 118,551 were performed to assess the proportion of ␤ 1 -and ␤ 2 ARs expressed in the heart ( Figure  1D ). In cardiac membranes from WT mice, the data were fit by a biphasic curve with 33.8Ϯ3.4% high-affinity binding sites (␤ 2 AR) and 66.2Ϯ3.4% low-affinity sites (␤ 1 AR). In the TG␤ 3 mice, however, the proportion was 51.8Ϯ0.7% ␤ 2 ARs and 48.5Ϯ0.8% ␤ 1 ARs (PϽ0.02 between WT and TG␤ 3 mice), which suggests that the expression of the endogenous ␤ 1 ARs was downregulated by Ϸ50%, from 35.5 fmol/mg in the WT mice to 16.7 fmol/mg in the TG␤ 3 mice. These data also demonstrate that there was no compensatory change in the ␤ 2 AR expression in TG␤ 3 hearts.
Physiological and Basal Hemodynamic Parameters in WT and TG␤ 3 Mice
To determine the functional consequences of ␤ 3 AR overexpression in the heart, cardiac catheterization was performed and hemodynamic measurements were recorded. As shown in Table 1 , TG␤ 3 mice showed a significantly lower left ventricular (LV) systolic pressure and reduced LV dP/dt max and LV dP/dt min compared with WT mice. There was no difference in heart rate or LV end-diastolic pressure. Interestingly, in the TG␤ 3 mice, LV weight was lower, resulting in a lower LV/BW ratio than in WT mice. Morphometric analysis of the hearts, however, revealed no differences in myocyte size between the WT and TG␤ 3 hearts (2365Ϯ97 m 2 , nϭ100, versus 2555Ϯ88 m 2 , nϭ100, respectively, PϽ0.147), suggesting that overexpression of ␤ 3 AR results in a decreased number of cells or a reduced amount of nonmyocyte tissue.
Echocardiography in Conscious WT and TG␤ 3 Mice
Because anesthesia can affect the contractile state of the ventricle, we sought to measure echocardiographic parameters in conscious mice. Chamber dimensions, wall thickness, % fractional shortening, and heart rate did not show any difference between WT and TG␤ 3 mice ( Table 2 ).
Effect of Isoproterenol on Hemodynamics in WT and TG␤ 3 Mice
To determine whether the ␤ 1 /␤ 2 /␤ 3 AR agonist isoproterenol could augment contractile function in the TG␤ 3 mice, hemodynamic measurements were made before and after isoproterenol administration. LV contractility, as assessed by LV dP/dt max at baseline conditions, was lower in TG␤ 3 mice than in WT mice (6664Ϯ388 mm Hg/s, nϭ10, versus 9470Ϯ921 mm Hg/s, nϭ9, PϽ0.02, Figure 2A , Table 1 ), whereas the effect of isoproterenol on LV dP/dt max was comparable between TG␤ 3 and WT mice (Figure 2A) . To further characterize the increase in ⌬LV dP/dt max with isoproterenol, the TG␤ 3 mice were pretreated with the nonselective ␤ 1 /␤ 2 AR antagonist propranolol. As shown, the positive inotropic effect of isoproterenol was completely abolished by pretreatment with propranolol in WT mice; a small but significant increase in contractility was still observed, however, in the TG␤ 3 mice ( Figure 2B ), indicating that a small fraction of the positive inotropic action of isoproterenol in TG␤ 3 mice may be attributed to the stimulation of overexpressed ␤ 3 ARs. 
Effect of the Selective ␤ 3 AR Agonist L755,507 on Hemodynamics in WT and TG␤ 3 Mice
To test directly whether stimulation of ␤ 3 ARs could augment contractility, hemodynamic parameters in WT and TG␤ 3 mice were measured in response to the selective human ␤ 3 AR agonist L-755,507. This compound is Ͼ1000-fold more selective for the activation of the ␤ 3 AR than for the ␤ 1 AR and has no measurable ␤ 2 AR agonist activity. 16 As shown in Figure 3A and 3B, L-755,507 (0.25 to 4.0 g IV) led to a marked increase in cardiac contractility in TG␤ 3 mice (nϭ10) that was completely absent in WT mice (nϭ5). Similarly, a large dose-dependent increase in heart rate in response to L-755,507 was also observed in TG␤ 3 mice and was again absent in WT mice ( Figure 3C ). There was no significant difference in the response of LV pressure to L-755,507 between WT and TG␤ 3 mice ( Figure 3D ). These results indicate that L-755,507 acts selectively on the human ␤ 3 AR and exerts positive inotropic and chronotropic actions in TG␤ 3 mice.
P-V Loops in WT and TG␤ 3 Mice
To rigorously investigate whether basal function was different in TG␤ 3 mice and WT mice, as suggested by Table 1 and Figures 2A and 3A , we obtained end-systolic P-V relations for both groups (Figure 4B and 4C) . Under basal conditions, the end-systolic P-V relation was curvilinear and the slope, E max Ј, of TG␤ 3 mice at baseline was comparable to that of WT mice ( Table 3 ). The administration of L-755,507 resulted in a steeper and more curvilinear end-systolic P-V relation only in the TG␤ 3 mice ( Figure 4B and 4C, Table 3 ). Furthermore, no significant difference in the volume intercept of the end-systolic P-V relation, LV end-systolic volume, or LV end-diastolic volume was observed between WT and TG␤ 3 mice. These data show that overexpression of the ␤ 3 AR does not affect the basal contractile state of the ventricle but can result in a significant enhancement of contractility with administration of L-755,507. Interestingly, whereas baseline LV dP/ dt max suggested depressed contractility in TG␤ 3 mice, a more rigorous analysis using P-V data showed basal contractility similar to that of WT mice. This is in agreement with known limitations of using LV dP/dt max as an index of contractile function. 14
Characterization of ␤ 3 AR Signaling in TG␤ 3 Hearts
To investigate the mechanism by which the selective stimulation of the ␤ 3 AR in the TG␤ 3 mice enhances contractility, biochemical analysis of the physical coupling of the receptor to its cognate G protein and measurement of adenylyl cyclase activity were performed. The agonist-mediated activation of the G protein ␣-subunit was measured by the quantitative binding of the radiolabeled nonhydrolyzable GTP analog [ 35 S]GTP␥S. Figure 5A shows that stimulation with L-755,507 results in GTP␥S loading only in TG␤ 3 membranes (1.33Ϯ0.04-fold over basal) and not in WT. To determine whether L-755,507-mediated GTP␥S loading in TG␤ 3 membranes is due to incorporation into G s or G i , TG␤ 3 mice were treated with PTX (0.1 g/g BW) overnight. GTP␥S loading stimulated by the G i -coupled A 1 adenosine receptor agonist N 6 -cyclopentyladenosine (CPA) was completely abrogated in the PTX-treated sample, confirming G i blockade by PTX ( Figure 5A) . Stimulation of the PTX-treated TG␤ 3 membranes with L-755,507 resulted in GTP␥S loading that was not significantly different from that observed in the untreated TG␤ 3 membranes. These data show that the overexpressed human ␤ 3 ARs in the TG␤ 3 mice are coupled mostly to non-G i proteins.
To assess the functional coupling of the overexpressed human ␤ 3 AR to G s in the TG␤ 3 mice, L-755,507-stimulated adenylyl cyclase activity was measured in cardiac membranes prepared from WT and TG␤ 3 hearts. The L-755,507-stimulated adenylyl cyclase activity in TG␤ 3 membranes was 1.6-fold over basal, whereas there was no stimulation in WT membranes ( Figure 5B ). In addition, there was no measurable increase in basal cyclase activity in the TG␤ 3 membranes compared with WT controls (Figure 5B, legend) . This observation suggests that despite the marked overexpression of ␤ 3 ARs, they are functionally inactive until specifically stimulated with a ␤ 3 agonist.
Discussion
Numerous studies have shown that stimulation of ␤ 1 -and ␤ 2 ARs in intact animals or cardiac preparations can lead to positive chronotropic and inotropic effects. Conversely, from initial work, 5, 8, 17 it appears that stimulation of ␤ 3 ARs can lead to a negative inotropic effect. To study the potential for the ␤ 3 AR to affect cardiac function, a transgenic mouse model was constructed that overexpresses the human ␤ 3 AR. The most salient feature of this model is enhanced cardiac contractility after intravenous injection of a selective ␤ 3 AR agonist, L-755,507. The increase in LV dP/dt max is attributable to the overexpression of ␤ 3 AR, because WT animals showed no enhancement of contractility with administration of the ␤ 3 AR agonist. Furthermore, in TG␤ 3 mice, administration of isoproterenol could overcome the blockade produced by pretreatment with the selective ␤ 1 -and ␤ 2 AR antagonist propranolol. Unfortunately, the unavailability of a specific ␤ 3 AR antagonist without partial agonist activity hampers the ability to further dissect the inotropic effect of isoproterenol in the TG␤ 3 mice. Another characteristic of the TG␤ 3 mouse is the downregulation of its endogenous ␤ 1 ARs by 50%. This result was not totally unexpected, because in the ␤ 3 AR knockout mouse, 18 the mRNA levels for ␤ 1 AR are upregulated in white and brown adipose tissues, whereas those for ␤ 2 AR are unchanged, suggesting a compensatory regulation of ␤ 1 -and ␤ 3 AR gene expression.
Gauthier et al 8 initially described functional coupling of the ␤ 3 AR to G i when stimulated with the ␤ 3 AR agonist BRL37344, resulting in negative inotropic effects in the human heart. Subsequently, negative inotropic effects of BRL37344 have been demonstrated in the isolated guinea pig heart. 17 A similar conclusion was inferred from studies in ␤ 3 AR-knockout mice, in which isoproterenol produced an augmented contractile response in comparison to WT mice. 5 In our study, however, ␤ 3 AR-G s coupling is clearly evident in the TG␤ 3 mouse model from the PTX-insensitive GTP␥S loading, the activation of adenylyl cyclase in cardiac membranes, and the in vivo positive inotropic effect caused by selective ␤ 3 AR stimulation. The reason for the apparent disparity between the results presented in this work and those of Gauthier et al 8 is unknown. They may be attributable, however, to the use of different ␤ 3 AR agonists or to different experimental models, ie, overexpression of human ␤ 3 AR in a mouse versus endogenous ␤ 3 AR in human endomyocardial biopsies or in guinea pig heart. Nonetheless, the ␤ 3 AR-G s coupling described in the TG␤ 3 mouse is consistent with reports of ␤ 3 AR dually coupling to G s and G i in a variety of cell types. 6, 7 Stimulation of ␤ 3 ARs in these models led to increased adenylyl cyclase activity, despite potential inhibitory effects from its coupling to G i . 2 In addition to the studies describing ␤ 3 AR activation in heart, there is evidence of a vasodilatory effect after ␤ 3 AR agonist treatment. 19 In conscious dogs, ␤ 3 AR stimulation with selective agonists induced marked peripheral vasodilation and positive inotropic and chronotropic effects. 20, 21 It is notable that in WT mice, the selective rodent ␤ 3 AR agonist CL316243 leads to a hypotensive response, and in ␤ 1 -/␤ 2 AR knockout mice, this effect is augmented. 22 These effects do not appear to be directly related to ␤ 3 AR stimulation of cardiac myocytes, however, because CL316243 has no chronotropic or inotropic effects in atrial or ventricular preparations from these knockout animals. 22 The variability of the cardiac and vascular responses to ␤ 3 AR agonists in different species highlights the fact that the function of the ␤ 3 AR in these tissues is still poorly understood.
It has been shown that during chronic heart failure, the cardiac ␤ 1 -adrenergic receptors are downregulated, leading to a deficiency in contractility. 23 We show that in this transgenic mouse model with cardiac-restricted overexpression, the human ␤ 3 AR is quiescent until stimulated with a selective agonist, at which point there is a marked augmentation in LV contractility. In addition, because the ␤ 3 AR is relatively insensitive to catecholamines, it would be minimally activated by endogenous catecholamines. Taken together, this approach could have important therapeutic potential in patients with heart failure, in which delivery of the human ␤ 3 AR by gene therapy approaches to the heart could provide a functionally inactive signaling protein that becomes activated only when a highly selective agonist is exogenously administered. E max indicates slope of end-systolic P-V relation (ESPVR) at volume intercept; a, curvilinearity coefficient; V 0 , volume intercept of ESPVR; r, correlation coefficient of the nonlinear fitting of ESPVR; V es , LV end-systolic volume; and V ed , LV end-diastolic volume. Mice were 4 months of age at the time of study. *PϽ0.01, †PϽ0.005 TG␤ 3 at L755,507 vs TG␤ 3 at Basal. No significant differences were found for TG␤ 3 at basal vs WT at basal. Figure 5 . Characterization of ␤ 3 AR signaling in cardiac membranes from TG␤ 3 and WT mice. A, WT (nϭ7), PTX-treated WT (nϭ8), TG␤ 3 (nϭ8), and PTX-treated TG␤ 3 (nϭ6) cardiac membranes were stimulated with 10 mol/L L-755,507, 10 mol/L isoproterenol (Iso), or 10 mol/L CPA and assayed for [ 35 S]GTP␥S loading. Activation by L-755,507 and isoproterenol was significantly different between WT and TG␤ 3 membranes (*PϽ0.004) and by CPA in TG␤ 3 vs TG␤ 3 ϩPTX and WT vs WTϩPTX membranes ( †PϽ0.0004). Basal levels of GTP␥S bound were 35.0Ϯ8.0 (WT), 21.5Ϯ2.5 (WTϩPTX), 22.5Ϯ4.5 (TG␤ 3 ), and 20.0Ϯ3.0 (TG␤ 3 ϩPTX) fmol/mg protein. B, TG␤ 3 (nϭ4) and WT (nϭ4) cardiac membranes were stimulated with various concentrations of L-755,507 and assayed for adenylyl cyclase activity. Basal activities of TG␤ 3 and WT membranes were 10.8Ϯ1.0 and 10.4Ϯ0.6 pmol cAMP · min Ϫ1 · mg protein Ϫ1 , respectively.
